×
About 10,765 results

ALLMedicine™ Erythropoietin Center

Research & Reviews  3,497 results

Erythropoietic effects of vadadustat in patients with anemia associated with chronic ki...
https://doi.org/10.1002/ajh.26644
American Journal of Hematology; Koury MJ, Agarwal R et. al.

Jun 26th, 2022 - Patients with chronic kidney disease develop anemia largely because of inappropriately low erythropoietin production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open-label, clinical trials in dialysis-depe...

Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery
https://clinicaltrials.gov/ct2/show/NCT04856618

Jun 24th, 2022 - Cardiac surgery is one of the clinical surgical specialties that carries a particularly high risk for patients to suffer from severe bleeding perioperatively and consequent anemia, which subsequently requires transfusion of allogeneic blood. Altho...

Mechanisms Accounting for Unexplained Anemia in the Elderly
https://clinicaltrials.gov/ct2/show/NCT01572506

Jun 24th, 2022 - Anemia occurs commonly and is associated with adverse outcomes in the elderly. In approximately one third of anemia cases in patients over the age of 65 years, the cause of anemia is not readily apparent (unexplained anemia or UA). Of the various ...

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red...
https://clinicaltrials.gov/ct2/show/NCT04717414

Jun 24th, 2022 - Permitted Concomitant Medications and Procedures Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their r...

Myelodysplastic Syndromes Treatment Protocols
https://emedicine.medscape.com/article/2006494-overview

Jun 23rd, 2022 - Treatment Protocols Treatment recommendations for myelodysplastic syndromes (MDS) are based on a patient’s Revised International Prognostic Scoring System score in addition to evaluation of a patient’s performance status and molecular genetic test...

see more →

Guidelines  3 results

KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations ...
https://doi.org/10.1111/j.1440-1797.2011.01535.x
Nephrology (Carlton, Vic.); McMahon LP, MacGinley R et. al.

Nov 3rd, 2011 - KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents.|2011|McMahon LP,MacGinley R, ,|blood,etiology,therapy,therapeutic use,standards,analysis,standards,complica...

Removal of erythropoietin from anaemia trauma practice guideline does not increase red ...
https://doi.org/10.1016/j.injury.2009.06.007
Injury Christmas AB, Camp SM et. al.

Jul 15th, 2009 - We previously demonstrated that utilization of erythropoietin (r-EPO) did not significantly reduce blood utilization in trauma patients. We undertook this study to analyze blood utilization 1 year after r-EPO removal from our trauma service anaemi...

Is there a role for erythropoietin in neonatal medicine?
https://doi.org/10.1016/j.earlhumdev.2008.06.002
Early Human Development; Mainie P

Jul 26th, 2008 - Since it was first cloned in 1985, the therapeutic potential of recombinant human erythropoietin in the neonatal hyporegenerative anaemias has been studied-the anaemia of prematurity and haemolytic disease of the newborn. Between 60% and 100% of p...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  539 results

Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery
https://clinicaltrials.gov/ct2/show/NCT04856618

Jun 24th, 2022 - Cardiac surgery is one of the clinical surgical specialties that carries a particularly high risk for patients to suffer from severe bleeding perioperatively and consequent anemia, which subsequently requires transfusion of allogeneic blood. Altho...

Mechanisms Accounting for Unexplained Anemia in the Elderly
https://clinicaltrials.gov/ct2/show/NCT01572506

Jun 24th, 2022 - Anemia occurs commonly and is associated with adverse outcomes in the elderly. In approximately one third of anemia cases in patients over the age of 65 years, the cause of anemia is not readily apparent (unexplained anemia or UA). Of the various ...

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red...
https://clinicaltrials.gov/ct2/show/NCT04717414

Jun 24th, 2022 - Permitted Concomitant Medications and Procedures Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their r...

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
https://clinicaltrials.gov/ct2/show/NCT03169881

Jun 22nd, 2022 - Advances in neonatal care have led to significant improvements in the survival of the nearly 60,000 very low birth weight (VLBW) infants born each year in the U.S. Improving neurodevelopmental outcomes for these preterm infants continues to be a m...

Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants
https://clinicaltrials.gov/ct2/show/NCT01235923

Jun 21st, 2022 - Erythropoietin (Epo) increases and maintains hematocrit using once weekly dosing in adults with anemia due to end stage renal disease. Epo is used in preterm infants to treat the anemia of prematurity, but has not been studied using once weekly do...

see more →

News  261 results

Sequencing MF Therapies and Novel Combinations
https://www.onclive.com/view/sequencing-mf-therapies-and-novel-combinations

Feb 28th, 2022 - Ruben Mesa, MD: Why don’t we pivot a little in terms of some of the combinations that are being looked at and how we might even weave it in? Jamile, we have pelabresib and rux [ruxolitinib], and we have some other things we certainly have done his...

Use of High-Dose Iron in Dialysis in US Tracks PIVOTAL Trial
https://www.medscape.com/viewarticle/968908

Feb 22nd, 2022 - A little over 3 years ago, researchers reported findings from PIVOTAL, the largest prospective, randomized trial to assess an aggressive versus conservative iron-repletion strategy in patients with end-stage kidney disease on hemodialysis, in The ...

What to Know About Polycythemia Vera and Treatment Options
https://www.onclive.com/view/what-to-know-about-polycythemia-vera-and-treatment-options

Jan 25th, 2022 - Ruben Mesa, MD: Pivoting back with earlier disease, Angela, why don’t you walk us through the diagnosis and kind of initial assessment of polycythemia vera [PV]? Angela Fleischman, MD, PhD: Many times, someone or a hematologist will be referred...

Novel Vaccine Induces Durable Remissions in Patients With Advanced Lymphoma
https://www.onclive.com/view/novel-vaccine-induces-durable-remissions-in-patients-with-advanced-lymphoma

Oct 6th, 2021 - Joshua Brody, MD Director, Lymphoma Immunotherapy Program Icahn School of Medicine Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions. Three bro...

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms
https://www.onclive.com/view/momelotinib-trial-seeks-to-address-myelofibrosis-symptoms

Oct 6th, 2021 - Momelotinib, an orally administered novel agent, is being evaluated in a phase 3 trial in patients with symptomatic and anemic myelofibrosis (MF), a population that experts say is in need of new options. The MOMENTUM trial (NCT04173494) will rando...

see more →

Patient Education  1 results see all →